On December 7, the British pharmaceutical company GSK said that its antibody treatment for COVID-19 (sotrovimab) in collaboration with the biotechnology company Vir Technology (USA) was effective against all mutations. Variation of the Omicron variant of the SARS-CoV-2 virus, citing new data from early-stage studies.

 Sotrovimab 

According to GSK, the data suggest that sotrovimab therapy is effective against all mutations in the spike protein (37 mutations) of the Omicron variant identified to date.

In other preclinical data, sotrovimab was shown to be resistant to major mutations of the Omicron variant.

Sotrovimab's mechanism is to attach to the spike protein on the surface of the SARS-CoV-2 virus, but the Omicron variant was found to have many mutations in that spike protein.

GSK Chief Scientific Officer Hal Barron states that preclinical data have demonstrated that the monoclonal antibody sotrovimab is active against the Omicron variant as well as all other variants recognized by the World Health Organization (WHO). WHO identified to date.

To evaluate the effectiveness of sotrovimab therapy, Mr.Barron, GSK and Vir generated mock virus with the same key mutations as in all variants of the SARS-CoV-2 virus that have emerged to date and have conducted experiments.